PFO ACCESS Registry

Expanded access is currently available for this treatment.
Verified August 2014 by AGA Medical Corporation
Sponsor:
Information provided by (Responsible Party):
AGA Medical Corporation
ClinicalTrials.gov Identifier:
NCT00583401
First received: December 21, 2007
Last updated: August 20, 2014
Last verified: August 2014

December 21, 2007
August 20, 2014
Not Provided
Not Provided
Not Provided
Not Provided
Complete list of historical versions of study NCT00583401 on ClinicalTrials.gov Archive Site
Not Provided
Not Provided
Not Provided
Not Provided
 
PFO ACCESS Registry
Not Provided

Closure of Patent Foramen Ovale with the AMPLATZER® PFO OCCLUDER in patients with at least two cryptogenic strokes due to presumed paradoxical embolism through a patent foramen ovale and who have failed conventional therapy.

Not Provided
Expanded Access
Not Provided
Not Provided
  • Patent Foramen Ovale
  • Stroke
Device: Device closure with the AMPLATZER PFO Occluder
Device closure with the AMPLATZER PFO Occluder
Not Provided
Not Provided

*   Includes publications given by the data provider as well as publications identified by ClinicalTrials.gov Identifier (NCT Number) in Medline.
 
Available
Not Provided
Not Provided
Not Provided

Inclusion Criteria:

  • PFO
  • recurrent stroke
  • failed antiplatelet/anticoagulant therapy

Exclusion Criteria:

  • INR outside of 2-3 intracardiac thrombus (subjects may be enrolled after resultion of thrombus)
Both
Not Provided
Not Provided
Contact: Karen Cook kcook@sjm.com
Not Provided
 
NCT00583401
AGA-011, G060145
Not Provided
AGA Medical Corporation
AGA Medical Corporation
Not Provided
Not Provided
AGA Medical Corporation
August 2014

ICMJE     Data element required by the International Committee of Medical Journal Editors and the World Health Organization ICTRP